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Abstract
Background
Refugees and other select visa holders are recommended to receive a domestic medical
examination within 90 days after arrival to the United States. Limited data have been pub-
lished on the coverage of screenings offered during this examination across multiple resettle-
ment states, preventing evaluation of this voluntary program’s potential impact on postarrival
refugee health. This analysis sought to calculate and compare screening proportions among
refugees and other eligible populations to assess the domestic medical examination’s impact
on screening coverage resulting from this examination.
Methods and findings
We conducted a cross-sectional analysis to summarize and compare domestic medical
examination data from January 2014 to December 2016 from persons receiving a domestic
medical examination in seven states (California, Colorado, Minnesota, New York, Kentucky,
Illinois, and Texas); one county (Marion County, Indiana); and one academic medical center
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in Philadelphia, Pennsylvania. We analyzed screening coverage by sex, age, nationality,
and country of last residence of persons and compared the proportions of persons receiving
recommended screenings by those characteristics. We received data on disease screen-
ings for 105,541 individuals who received a domestic medical examination; 47% were
female and 51.5% were between the ages of 18 and 44. The proportions of people undergo-
ing screening tests for infectious diseases were high, including for tuberculosis (91.6%
screened), hepatitis B (95.8% screened), and human immunodeficiency virus (HIV; 80.3%
screened). Screening rates for other health conditions were lower, including mental health
(36.8% screened). The main limitation of our analysis was reliance on data that were col-
lected primarily for programmatic rather than surveillance purposes.
Conclusions
In this analysis, we observed high rates of screening coverage for tuberculosis, hepatitis B,
and HIV during the domestic medical examination and lower screening coverage for mental
health. This analysis provided evidence that the domestic medical examination is an oppor-
tunity to ensure newly arrived refugees and other eligible populations receive recommended
health screenings and are connected to the US healthcare system. We also identified knowl-
edge gaps on how screenings are conducted for some conditions, notably mental health,
identifying directions for future research.
Author summary
Why was this analysis done?
• Newly arrived refugees, special immigrant visa holders, asylees, Cuban/Haitian entrants,
and other select visa types are eligible for a domestic medical examination conducted
shortly after they arrive in the US. The purpose of this examination is to identify health
conditions requiring further treatment and to connect these populations to the US
healthcare system.
• Several investigations have reported on health conditions identified during the domestic
medical examination, but none have assessed the impact of this examination on recom-
mended health screening coverage for these populations.
• We sought to better understand how the domestic medical examination impacts screen-
ing coverage among eligible populations in selected jurisdictions in the US.
What did the authors do and find?
• We collected data from domestic screening examinations conducted between 2014 and
2016 from nine sites across the US, including basic demographic data and specific health
screening tests administered during the examination.
• We analyzed proportions of people screened for tuberculosis, human immunodefi-
ciency virus (HIV), hepatitis B and C, various parasites, blood lead level, and mental
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health conditions. We also described screening coverage by age, sex, visa type, examina-
tion year, nationality, and country of last residence.
• Among the 105,541 persons who received a domestic screening examination, most per-
sons were screened for tuberculosis (91.6%), hepatitis B (95.8%), and HIV (80.3%).
Mental health screening was lower (36.8%).
What do these findings mean?
• The domestic medical examination is an effective opportunity to screen eligible newly
arrived populations for several health conditions, particularly tuberculosis, HIV, and
hepatitis B, but may not be as effective an opportunity for mental health screening.
• The high screening coverage during the domestic screening examination ensures that
refugees and other eligible populations are healthily integrated into receiving
communities.
• Future analyses could be conducted to better understand why screening rates for mental
health are low during the domestic medical examination and how effectively the exami-
nation links individuals to the US healthcare system.
• The main limitation of our analysis was our use of nonstandard data collected primarily
for programmatic rather than surveillance purposes.
Introduction
Between 2014 and 2016, the US welcomed an annual average of 75,000 refugees, 9,900 Special
Immigrant Visa holders (SIVHs), and 23,000 persons granted asylum (asylees) [1]. Before US
resettlement, these populations may have spent years without access to routine, preventive
healthcare [2]. To address healthcare gaps and ensure healthy resettlement in the US, the
immigration process includes multiple health screening exams and interventions [3].
Under section 325 of the Public Health Service Act (42 USC 252) and sections 212 and 232
of the Immigration and Nationality Act (8 USC 1182, 1222), refugees, SIVHs, and derivative
asylees (persons applying outside of the US) are required to undergo a medical exam before
admission to the US to detect the presence of inadmissible health conditions. These medical
exams are conducted by physicians contracted by the US Department of State and are per-
formed according to US Centers for Disease Control and Prevention (CDC) Technical Instruc-
tions for the Medical Examination of Aliens [3]. In addition, US-bound refugees (but not other
visa types) are eligible for overseas health interventions such as predeparture screening, the
voluntary Vaccination Program for US-bound Refugees, and the presumptive parasite treat-
ment program [3]. Asylees granted their status after US arrival do not receive overseas screen-
ing or interventions [4].
After US arrival or certification, refugees, SIVHs, asylees, Cuban/Haitian entrants (parol-
ees), Amerasians (a visa status available to children born in Vietnam of US citizen fathers after
January 1, 1962, and before January 1, 1976, and their eligible dependents), and certified vic-
tims of human trafficking are eligible for benefits, including a recommended medical
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screening examination that addresses health conditions diagnosed overseas, identifies addi-
tional health concerns, and connects the individuals with the US healthcare system [3,5]. CDC
provides Guidelines for the U.S. Domestic Medical Examination for Newly Arriving Refugees,
but state or local refugee health programs independently coordinate the examination, and
these guidelines may be adapted for local use [6,7]. The comprehensive examination includes a
medical history and physical examination, screening for select communicable diseases, nutri-
tional status assessment, blood lead screening for children <17 years old, and immunization
administration according to US schedules [7].
Examinations and interventions provided during the initial resettlement period ensure that
refugees and other eligible populations are healthily integrated into receiving communities
and are ready to begin work and school. Further, the domestic examination is usually the first
contact the individual has with the US healthcare system and possibly the first time he/she is
screened for certain health conditions or receives preventive healthcare [8,9].
Assessing the impact of the domestic examination on the recipient as well as on the receiv-
ing community has been challenging. Data from these examinations are not routinely collected
at the national level, and state capacity to collect and analyze these data varies. In a review of
the literature, we found that most analyses based on domestic medical examination data occur
at the clinic, state, or local levels [10] and may not represent all recipients of refugee health pro-
gram services, given the heterogeneity of these populations. Where domestic examination data
are pooled across states or sites, analyses are generally limited to a particular condition (e.g.,
hepatitis B, lead) or population (e.g., children) [11–14]. Finally, we identified few analyses that
reported the proportion of persons screened by condition during the domestic medical exami-
nation [10–12], which, to our knowledge, prevents assessment of the impact of the domestic
examination on screening coverage. Accordingly, we conducted, to our knowledge, a novel
analysis to assess screening coverage during the domestic medical examination on screening
coverage for various conditions by calculating and comparing screening proportions among
refugees and other visa holders by select demographic characteristics.
Methods
We conducted a retrospective, cross-sectional analysis of data derived from domestic medical
examinations administered to refugees, SIVHs, asylees, parolees, and victims of trafficking
between January 1, 2014, and December 31, 2016, in seven states (California, Colorado, Min-
nesota, New York, Kentucky, Illinois, and Texas); one county (Marion County, Indiana); and
one academic medical center in Philadelphia, Pennsylvania. These sites provided their data as
part of the CDC-funded CK12-1205 Strengthening Surveillance for Diseases among Newly
Arrived Immigrants and Refugees nonresearch cooperative agreement administered by CDC.
At least one representative of each site participated in the data collection and analysis of data.
Although this is a convenience sample and not generalizable to all refugees in the US, the data
set includes data from three states (California, Texas, and New York) with the highest volume
of refugee, asylee, and SIVH arrivals between 2014 and 2016 and represents 28% of all refugee,
asylee, and SIVH arrivals to the US during the same period. As part of a larger data collection
effort, this analysis was not guided by a specific prospective analysis plan. However, the vari-
ables collected for analysis were outlined in a protocol used for ethical determination and
shared with site partners contributing data. After data collection, we assessed the quality and
availability of our data and identified appropriate analyses, including this descriptive analysis
to assess screening coverage. This activity received a nonresearch determination from a CDC
human subjects adviser and was exempt from further ethics review.
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We suggested the variables and formats to compile the data to the nine participating site
data partners. If partners could not provide those variables, they shared comparable raw data
with explanations for missing variables or data. We then recoded the raw data for inclusion in
the combined data set. Most data were collected from the state or local refugee health program
databases, but some partners obtained data from other state or local programs (e.g., tuberculo-
sis [TB] control or lead poisoning) because those data were not in the refugee program data-
base. Some sites’ restrictions on sharing personally identifying information prevented them
from sharing birth and arrival dates; instead, they provided age at arrival and arrival year as
proxy variables. Sites either provided nationality and country of last residence or shared a
unique identifier we used to link to the US Department of State’s Worldwide Refugee Admis-
sions Processing System (78.1% of records linked) and CDC’s Electronic Disease Notification
system (74.0% linked) to obtain these two variables. Nationality or country of last residence
were left blank or imputed from country of birth for records that did not match. Other than
the unique identifier and birth date, we did not collect or store personally identifying informa-
tion. Data were transmitted to CDC via secure file transfer and stored behind CDC’s firewall
and physical security measures; access to raw data was limited to a few CDC refugee health
program staff.
Demographic variables were age (in years), sex, arrival year, visa status, nationality, and coun-
try of last residence (generally the country of asylum for refugees). For our outcome of interest,
screening status, we created a bivariate variable of “screened,” which included all persons a site
reported to be screened, regardless of outcome, and “not screened,” which included persons who
were not screened; screening status was known for all persons. We examined results for condi-
tions with screening recommended by CDC’s Guidelines for the U.S. Domestic Medical Examina-
tion for Newly Arriving Refugees (Table 1): TB (using interferon gamma release assays [IGRAs]
or tuberculin skin tests [TST]; screening tests do not distinguish between latent TB infection
[LTBI] and TB disease), hepatitis B (results from hepatitis B surface antigen [HBsAg] and hepati-
tis B core antibody [anti-HBc] and/or hepatitis B surface antibody [anti-HBs] testing, when avail-
able), hepatitis C, malaria, strongyloidiasis, schistosomiasis, other intestinal parasites, syphilis,
gonorrhea, chlamydia, human immunodeficiency virus (HIV), blood lead levels (among children
<17 years old), and mental health. For most conditions, we were unable to collect detailed infor-
mation on the method of screening used by partners. We assumed the sites conducted screening
or testing in accordance with the CDC’s Guidelines for the U.S. Domestic Medical Examination
for Newly Arriving Refugees (Table 1).
We used SAS 9.4 (SAS Institute, Cary, NC) to combine, clean, and standardize data from
each site, resulting in an initial data set of 107,162 records meeting our inclusion criteria. A
unique identifier was available for six sites (n = 90,209, 84.2%); data sharing laws in three sites
(n = 16,953, 15.8%) prevented sharing of unique identifiers. We used the unique identifier to
remove 1,621 (1.8%) duplicate records. Most duplicate records (n = 1,430, 88.2%) were from
one site and related to a reporting error unlikely to have been repeated in other sites, in which
the corrected rate of duplicate records was 0.2%. Therefore, we estimate the potential number
of duplicate records remaining in the portion of data set without unique identifiers to be low
(approximately 0.2%). We presented data individually for the top 10 countries of nationality
and last residence by arrival volume and grouped the remaining countries into an “other”
category. Denominators for each condition consisted of the total number of persons for whom
screening status (e.g., screened or not screened) was available, which resulted in different
denominators by condition. For each condition, we excluded data from sites that were only
able to provide positive testing results without providing data on how many people were
screened for the condition or who did not routinely screen or report data on a specific condi-
tion. The denominators used to calculate proportions screened are reported in “Total” column
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of each table. We calculated frequencies and percentages and their 95% confidence intervals
(CIs) for demographic and screening variables and cross-tabulations for the number and pro-
portion of persons screened with valid results for each condition by age, sex, visa type, exami-
nation year, countries of nationality, and last residence and for TB only, the screening test
type. We used χ2 and Fischer exact tests to compare proportions screened by age, sex, visa
Table 1. Recommended health screenings of refugees and other eligible immigrants during the domestic medical screening examinations conducted in nine selected
US sites according to CDC guidelines, 2014–2016a.
Health Condition Populations Recommended for Screening Screening
Tuberculosis All groups IGRA and/or TST
Hepatitis B Virus All individuals who were born in or most recently lived in countries in
which the rate of chronic hepatitis B virus infection is >2%
(intermediate or highly endemic countries) and all individuals from
low-endemicity countries if they have hepatitis B virus risk factors or
are pregnant
HBsAg and anti-HBc (optional) and/or anti-HBs (optional)
Hepatitis C Virus High-risk groups, including people who have ever injected illegal
drugs, have body art (tattoos, piercings), are human
immunodeficiency virus positive, have a history of multiple sex
partners or sexually transmitted infections, have a mother positive for
hepatitis C virus, received blood products before migration, have a
history of chronic hemodialysis, or have other risk factors
Anti-HCV or RIBA or hepatitis C ribonucleic acid PCR
Malaria Sub-Saharan African refugees receiving no presumptive treatment
before departure or any person from a malaria-endemic country with
signs or symptoms of infection
Laboratory-confirmed via microscopy or rapid diagnostic test
Strongyloides Individuals without complete predeparture treatment Laboratory-confirmed microscopy or serology test
Schistosoma Individuals coming from sub-Saharan Africa without complete
predeparture treatment (most refugees are treated overseas)
Laboratory-confirmed microscopy or serology test
Intestinal Parasites Individuals with no predeparture treatment (most refugees from
Middle East, South and Southeast Asia, and Africa are treated
overseas)
Laboratory-confirmed stool ova and parasite test
Syphilis If no overseas testing documentation: (1) all persons�15 years of age,
regardless of the overseas results, and (2) refugees <15 years if they are
sexually active/have a history of sexual abuse, have a mother who tests
positive, are from a country endemic for other treponemal subspecies
Non-treponemal test (Venereal Disease Research Laboratory or
rapid plasma reagin)
Gonorrhea Anyone with symptoms or leukocyte esterase positive on urine sample
and women and children with history or risk of sexual assault
Laboratory-confirmed testing (not specified)
Chlamydia Sexually active women <25 years old, women >25 years old with risk
factors, women or children with sexual assault history or risk, anyone
with symptoms or are leukocyte esterase positive on urine sample
Laboratory-confirmed testing (not specified)
Human
Immunodeficiency
Virus
All groups (opt-out screening) Laboratory-confirmed testing (not specified)
Blood Lead All children 6 months to 16 years old Blood lead level from capillary or venous specimen (venous
preferred)
Mental Health Individuals >16 years old should be screened for symptoms of major
depression and posttraumatic stress disorder
RHS-15 or diagnosis or notation of mental condition including
posttraumatic stress disorder, depression, anxiety, adjustment
disorder, alcohol or substance abuse, and/or generalized anxiety
disorder
aThis table reflects CDC’s Guidelines for the U.S. Domestic Medical Examination for Newly Arriving Refugees in place during the period of this analysis (2014–2016).
Changes to the guidelines and broader implementation of overseas intervention programs occurred during and after the data collection for this analysis, which may
have affected domestic screening for some groups. Current guidelines can be found at https://www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/domestic-
guidelines.html
Abbreviations: anti-HBc, hepatitis B core antibody; anti-HBs, hepatitis B surface antibody; anti-HCV, hepatitis C antibody; CDC, Centers for Disease Control and
Prevention; HBsAg, hepatitis B surface antigen; IGRA, interferon gamma release assay; PCR, polymerase chain reaction; RHS, Refugee Health Screener; RIBA,
recombinant immunoblot assay; TST, tuberculin skin test
https://doi.org/10.1371/journal.pmed.1003065.t001
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type, exam year, nationality, and country of last residence. We considered differences in pro-
portions statistically significant at the 0.05 alpha level and examined 95% CIs to assess stra-
tum-specific differences in screening by characteristic. This analysis is reported per the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline
(S1 STROBE Checklist).
Results
Our analysis data set included 105,541 refugees and other eligible persons who received a
domestic medical examination between January 1, 2014, and December 31, 2016, in one of the
nine sites. Characteristics of the data set are reported by visa status in Table 2. All nine sites
provided screening data for TB, hepatitis B, HIV, and hepatitis C, resulting in a denominator
of 105,541 persons screened for those conditions (Table 3). Eight sites provided screening data
for malaria, schistosomiasis, strongyloidiasis, intestinal parasites, and sexually transmitted
infections (STIs), resulting in a denominator of 100,677 persons screened for these infections
(Tables 4 and 5). All nine sites provided blood lead screening data for children <17 years old,
which is the age recommendation for lead screening in CDC’s Guidelines for the U.S. Domestic
Medical Examination for Newly Arriving Refugees (lead screening denominator: 35,118,
Table 6). Finally, five sites provided mental health screening data for 27,712 persons (Table 6).
Four sites did not share mental health screening data because they either did not conduct men-
tal health screening at the time of the domestic screening examination or did not retain mental
health screening information in the data sources used for this analysis.
Approximately 51% of persons in our initial data set were between 18 and 44 years old, and
34.8% were under age 18 (Table 2). Fifty-three percent were male. Burma (16.8%), Iraq (15.8%),
Cuba (14.7%), Afghanistan (11.1%), and Somalia (8.0%) contributed the largest volumes of
arrivals by nationality (Table 2). The data set mostly comprised refugees (70.2%), Cuban/Hai-
tian parolees (14.1%), SIVHs (11.2%), and asylees (3.8%) (Table 2). Fifty percent of examina-
tions took place within 30 days of US arrival (Table 2). Timing of screening after arrival varied
by visa type (refugees and SIVH: median 27 days; parolees: 49 days; asylees: 57 days, Table 2),
consistent with anticipated flows through the resettlement process.
Most individuals (96,606 of 105,541; 91.6%, 95% CI 91.4–91.8) were screened for TB
(Table 3); of those, 89.0% were screened with an IGRA test. Screening differed significantly
by age, with 95.5% (95% CI 95.3–95.6, collapsed from Table 3) of those aged 6 years or older
screened for TB compared with 61.9% (95% CI 61.1–62.8) of children aged 5 and younger (χ2
p< 0.001). Screening was lowest among SIVH (86.6%, 95% CI 86.0–87.2) compared with all
visa types (91.6%, 95% CI 91.4–91.8). Afghans had the lowest proportion of persons screened
for TB (86.9%, 95% CI 86.3–87.6); Iranians had the highest (96.9%, 95% CI 96.5–97.3).
In our data set, hepatitis B virus (HBV) screening was reported for 101,004 of 105,541 per-
sons (95.8%, 95% CI 95.7–95.9) (Table 3). Screening coverage among children <5 years old
was lowest (86.0%, 95% CI 85.4–86.6);�98.3% of persons�45 years old were screened. A
lower proportion of SIVHs were screened (93.3%, 95% CI 92.9–93.8) compared with parolees
and asylees (�98.1%). Screening coverage was lowest among Ukrainians (91.9%, 95% CI,
90.5–93.3) and highest among Cubans (98.6%, 95% CI 98.4–98.8).
HIV screening was reported for 84,687 of 105,541 persons (80.3%, 95% CI 80.1–80.6)
(Table 3). Screening coverage differed significantly across age groups (χ2 p< 0.001), with the
lowest coverage among children less than 5 years old (65.0%, 95% CI 64.2–65.9). The percent-
age of adults�18 years old screened for HIV was 85.2% (95% CI 84. 9–85.4, data collapsed
from Table 3). Among top arrival nationalities, screening ranged from 65.2% (95% CI 63.8–
66.6) among Bhutanese to 94.6% (95% CI 94.2–95.0) among Cubans.
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Table 2. Demographic characteristics of persons receiving a domestic medical examination by visa status in nine US sites, 2014–2016.
Characteristics Visa Status
Total Asylee Parolee Refugees Special
Immigrant
Visa Holders
Othera
N Col% N Col% N Col% N Col% N Col% N Col%
Total (Row %) 105,451 100 4,044 3.8 14,915 14.1 74,025 70.2 11,801 11.2 666 0.6
Mean Age, Years (SD) 25.8 (17.1) 28.1 (16.1) 33.2 (13.0) 25.1 (17.8) 19.9 (14.4) 26.2 (16.1)
Age (Years)b
<5 12,096 11.5 213 5.3 358 2.4 9,023 12.2 2,447 20.7 55 8.3
5–17 24,614 23.3 930 23.0 989 6.6 19,882 26.9 2,651 22.5 162 24.3
18–44 54,255 51.5 2,267 56.1 10,906 73.1 34,506 46.6 6,215 52.7 361 54.2
45–64 11,714 11.1 552 13.7 2,411 16.2 8,258 11.2 417 3.5 76 11.4
65+ 2,762 2.6 82 2.0 251 1.7 2,347 3.2 70 0.6 12 1.8
Examination Year
2014 34,548 32.8 1,818 45.0 3,408 22.9 25,410 34.3 3,673 31.1 239 35.9
2015 33,358 31.6 1,240 30.7 6,168 41.4 22,533 30.4 3,190 27.0 227 34.1
2016 37,545 35.6 986 24.4 5,339 35.8 26,082 35.2 4,938 41.8 200 30.0
Sexc
Female 1,933 47.8 1,933 47.8 5,942 39.8 35,977 48.6 5,291 44.8 374 56.2
Male 2,111 52.2 2,111 52.2 8,970 60.1 38,036 51.4 6,509 55.2 288 43.2
Median Days Elapsed between Arrival and Examination (IQR) 30 (16–53) 57 (40–74) 49 (31–71) 27 (14–47) 27 (14–48) 47 (29–67)
Days from Arrival to Exam
<30 Days 53,070 50.3 595 14.7 3,558 23.9 42,284 57.1 6,450 54.7 183 27.5
30–90 Days 48,164 45.7 3,113 77.0 10,173 68.2 29,449 39.8 5,025 42.6 404 60.7
>90 Days 3,384 3.2 318 7.9 1,009 6.8 1,770 2.4 216 1.8 71 10.7
Unknown 833 0.8 18 0.5 175 1.2 522 0.7 110 0.9 8 1.2
Nationality
Afghanistan 11,736 11.1 191 4.7 33 0.2 2,397 3.2 8,977 76.1 138 20.7
Bhutan 4,221 4.0 6 0.2 4 0.0 4,201 5.7 4 0.0 6 0.9
Burma 17,749 16.8 29 0.7 9 0.1 17,674 23.9 29 0.3 8 1.2
Democratic Republic of Congo 6,554 6.2 28 0.7 �3 0.0 6,497 8.8 25 0.2 �3 0.5
Cuba 15,459 14.7 29 0.7 14,499 97.2 867 1.2 44 0.4 20 3.0
Iran 7,179 6.8 367 9.1 37 0.3 6,396 8.6 350 3.0 29 4.4
Iraq 16,605 15.8 389 9.6 24 0.2 14,172 19.1 1,963 16.6 57 8.6
Somalia 8,474 8.0 110 2.7 �3 0.0 8,288 11.2 44 0.4 30 4.5
Syria 4,258 4.0 82 2.0 �3 0.0 4,125 5.6 45 0.4 4 0.6
Ukraine 1,485 1.4 22 0.5 6 0.0 1,362 1.8 93 0.8 �3 0.3
Otherd 11,731 11.1 2,791 69.0 298 2.0 8,046 10.9 227 1.9 369 55.4
Last Residence
Afghanistan 8,475 8.0 162 4.0 29 0.2 998 1.4 7,153 60.6 133 20.0
Austria 5,173 4.9 84 2.1 33 0.2 4,773 6.5 270 2.3 13 2.0
Cuba 3,791 3.6 18 0.5 2,997 20.1 741 1.0 24 0.2 11 1.7
Iraq 8,781 8.3 131 3.2 15 0.1 7,089 9.6 1,499 12.7 47 7.1
Jordan 4,851 4.6 44 1.1 5 0.0 4,743 6.4 55 0.5 4 0.6
Kenya 4,361 4.1 19 0.5 �3 0.0 4,305 5.8 21 0.2 13 2.0
Malaysia 11,217 10.6 12 0.3 7 0.1 11,167 15.1 26 0.2 5 0.8
Nepal 4,319 4.1 117 2.9 4 0.0 4,188 5.7 4 0.0 6 0.9
Thailand 6,363 6.0 5 0.1 �3 0.0 6,338 8.6 16 0.1 �3 0.2
Turkey 5,586 5.3 45 1.1 �3 0.0 5,369 7.3 162 1.4 7 1.1
(Continued)
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Hepatitis C virus (HCV) screening was reported for 49,783 (47.2%, 95% CI 46.9–47.5) of
105,541 persons (Table 3). Screening coverage increased with age; 56.1% (95% CI 55.3–56.9,
data collapsed from Table 3) of adults 45 years and older at the time of their examination (ages
corresponding loosely to persons born between 1945 and 1965, a population with greater
HCV infection risk in the US) were tested for HCV; screening coverage among person <45
years old was 45.8% (95% CI 45.5–46.1, data collapsed from Table 3). Asylees had the highest
screening coverage (68.3%, 95% CI 66.9–69.8). The screening coverage of persons from coun-
tries with high or high-moderate HCV burden [15] included 68.2% (95% CI 65.8–70.5) of
Ukrainians, 42.7% (95% CI 41.5–43.9) of Congolese (Democratic Republic), and 41.5% (95%
CI 40.0–43.0) of Syrians.
Our data set consisted of 100,677 persons with data on screening coverage for malaria,
Strongyloides, Schistosoma, and other intestinal parasites. In this data set, 16,180 (16.1%, 95%
CI 15.8–16.3) persons were reported screened for malaria (Table 4). Asylees had the highest
screening coverage (51.4%, 95% CI 49.8–53.0). Screening declined from 23.9% (95% CI 23.5–
24.4) of persons receiving a domestic medical examination in 2014 to 3.6% (95% CI 3.4–3.8)
of persons arriving in 2016. Nationalities with the highest proportion of persons screened
included Iranians (48.8%, 95% CI 47.7–50.0) and Afghans (26.6%, 95% CI 25.7–27.4). People
with a last residence in Austria, Afghanistan, or Turkey had the highest screening percentage.
Of the 100,677 persons screened for intestinal parasites, 23,964 (23.8%, 95% CI 23.5–24.1)
were screened for Strongyloides infection (Table 4). Ukrainians (66.7%, 95% CI 64.3–69.2),
Table 2. (Continued)
Characteristics Visa Status
Total Asylee Parolee Refugees Special
Immigrant
Visa Holders
Othera
N Col% N Col% N Col% N Col% N Col% N Col%
Othere 42,534 40.3 3,407 84.3 11,816 79.2 24,314 32.9 2,571 21.8 426 64.0
Col% refers to the proportion of persons with characteristics using the total population (in first column) as denominator.
a“Other” visa category includes victims of trafficking, unaccompanied minors, and persons with an unspecified visa status.
bExcludes 10 individuals missing age.
cExcludes 20 individuals missing sex.
dIncludes persons with the following nationalities: Missing, Algeria, Andorra, Angola, Armenia, Austria, Azerbaijan, Bangladesh, Belarus, Belize, Benin, Botswana,
Brazil, Burkina Faso, Burundi, Cambodia, Cameroon, Canada, Central African Republic, Chad, Chile, China, Colombia, Republic of Congo, Costa Rica, Coˆte d’Ivoire,
Cyprus, Djibouti, Dominican Republic, Ecuador, Egypt, El Salvador, Eritrea, Estonia, Ethiopia, Fiji, Gabon, Gaza Strip/West Bank, Georgia, Germany, Ghana, Greece,
Grenada, Guatemala, Guinea, Haiti, Honduras, India, Indonesia, Ireland, Israel, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kuwait, Kyrgyzstan, Latvia, Lebanon,
Liberia, Libya, Malawi, Malaysia, Maldives, Mali, Mexico, Moldova, Mongolia, Morocco, Mozambique, Namibia, Nepal, the Netherlands, Nicaragua, Niger, Nigeria,
North Korea, Norway, Oman, Pakistan, Peru, Philippines, Poland, Polish, Qatar, Romania, Russia, Rwanda, Saudi Arabia, Senegal, Serbia, Sierra Leone, Solomon
Islands, South Africa, South Korea, South Sudan, Spain, Sri Lanka, Sudan, Sweden, Taiwan, Tajikistan, Tanzania, Thailand, Togo, Tunisia, Turkey, Turkmenistan,
Uganda, United Arab Emirates, Unknown, Uzbekistan, Venezuela, Vietnam, Yemen, Zambia, and Zimbabwe.
eIncludes persons with the following countries of last residence: Missing, Albania, Algeria, Armenia, Australia, Azerbaijan, Bahrain, Bangladesh, Belarus, Belize, Bhutan,
Botswana, Brazil, Burma, Burundi, Cambodia, Cameroon, Canada, Central African Republic, Chad, China, Colombia, Costa Rica, Coˆte d’Ivoire, Democratic Republic of
Congo, Djibouti, Dominican Republic, Ecuador, Egypt, El Salvador, Eritrea, Ethiopia, France, Gabon, Gaza Strip/West Bank, Germany, Ghana, Guatemala, Guinea,
Haiti, Honduras, Hong Kong, India, Indonesia, Iran, Israel, Italy, Kazakhstan, Kuwait, Kyrgyzstan, Latvia, Lebanon, Liberia, Libya, Malawi, Mali, Malta, Mauritania,
Mexico, Moldova, Mongolia, Morocco, Mozambique, Myanmar, Namibia, the Netherlands, Nicaragua, Nigeria, North Korea, Oman, Pakistan, Panama, Peru,
Philippines, Qatar, Republic of Congo, Romania, Russia, Rwanda, Saudi Arabia, Slovakia, Slovenia, Somalia, South Africa, South Korea, Spain, Sri Lanka, Sudan,
Sweden, Syria, Tajikistan, Tanzania, Togo, Trinidad and Tobago, Tunisia, Uganda, Ukraine, United Arab Emirates, United Kingdom, United States, Uzbekistan,
Venezuela, Vietnam, Yemen, Zambia, Zimbabwe.
Abbreviations: SD, standard deviation
https://doi.org/10.1371/journal.pmed.1003065.t002
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Table 3. Screening coverage of refugees and other eligible immigrants for tuberculosis infection, hepatitis B, HIV, and hepatitis C by demographic characteristics
during domestic medical screening examinations conducted in nine US sites, 2014–2016.
Characteristics Number and Proportion of Persons Screened
Total Tuberculosis Infection Hepatitis B HIV Hepatitis C
N Col% N Row% χ2
95% CI
N Row% χ2
95% CI
N Row% χ2
95% CI
N Row% χ2
95% CI
Total 105,451 100 96,606 91.6 91.4–
91.8
101,004 95.8 95.7–
95.9
84,687 80.3 80.1–
80.6
49,783 47.2 46.9–
47.5
Age (Years)a <0.001 <0.001 <0.001 <0.001
<5 12,096 11.5 7,489 61.9 61.1–
62.8
10,402 86 85.4–
86.6
7,862 65.0 64.2–
65.9
4,433 36.7 35.8–
37.5
5–17 24,614 23.3 22,628 91.9 91.6–
92.3
23,257 94.5 94.2–
94.8
18,275 74.3 73.7–
74.8
10,635 43.2 42.6–
43.8
18–44 54,255 51.5 52,445 96.7 96.5–
96.8
53,112 97.9 97.8–
98.0
46,105 85 84.7–
85.3
26,593 49 48.6–
49.4
45–64 11,714 11.1 11,351 96.9 96.6–
97.2
11,508 98.2 98.0–
98.5
10,034 85.7 85.0–
86.3
6,330 54 53.1–
54.9
65+ 2,762 2.6 2,683 97.1 96.5–
97.8
2,715 98.3 97.8–
98.8
2,402 87.0 85.7–
88.2
1,789 64.8 63.0–
66.6
Examination Year <0.001 <0.001 <0.001 <0.001
2014 34,548 32.8 31,788 92 91.7–
92.3
33,005 95.5 95.3–
95.8
27,148 78.6 78.2–
79.0
16,689 48.3 47.8–
48.8
2015 33,358 31.6 30,585 91.7 91.4–
92.0
32,294 96.8 96.6–
97.0
28,000 83.9 83.5–
84.3
15,980 47.9 47.4–
48.4
2016 37,545 35.6 34,233 91.2 90.9–
91.5
35,705 95.1 94.9–
95.3
29,539 78.7 78.3–
79.1
17,114 45.6 45.1–
46.1
Sexb <0.001 0.0012 <0.001 <0.001
Female 49,517 47 45,211 91.3 91.1–
91.6
47,325 95.6 95.4–
95.8
39,554 79.9 79.5–
80.2
23,767 48 47.6–
48.4
Male 55,914 53 51,386 91.9 91.7–
92.1
53,663 96 95.8–
96.1
45,130 80.7 80.4–
81.0
26,016 46.5 46.1–
46.9
Visa <0.001 <0.001 <0.001 <0.001
Refugee 74,025 70.2 67,685 91.4 91.2–
91.6
70,656 95.5 95.3–
95.6
56,341 76.1 75.8–
76.4
35,923 48.5 48.2–
48.9
Special Immigrant Visa Holder 11,801 11.2 10,221 86.6 86.0–
87.2
11,015 93.3 92.9–
93.8
9,806 83.1 82.4–
83.8
7,233 61.3 60.4–
62.2
Asylee 4,044 3.8 3,812 94.3 93.6–
95.0
3,967 98.1 97.7–
98.5
3,774 93.3 92.6–
94.1
2,763 68.3 66.9–
69.8
Cuban/Haitian Entrant (Parolees) 14,915 14.1 14,262 95.6 95.3–
96.0
14,722 98.7 98.5–
98.9
14,161 94.9 94.6–
95.3
3,493 23.4 22.7–
24.1
Other (Nonrefugees)c 666 0.6 626 94 92.2–
95.8
644 96.7 95.3–
98.1
605 90.8 88.7–
93.0
371 55.7 51.9–
59.5
Nationality <0.001 <0.001 <0.001 <0.001
Afghanistan 11,736 11.1 10,203 86.9 86.3–
87.6
10,982 93.6 93.3–
94.0
9,586 81.7 81.0–
82.4
7,163 61 60.2–
61.9
Bhutan 4,221 4 3,839 91.0 90.1–
91.8
3,984 94.4 93.7–
95.1
2,752 65.2 63.8–
66.6
1,851 43.9 42.4–
45.4
Burma 17,749 16.8 15,839 89.2 88.8–
89.7
16,786 94.6 94.2–
94.9
13,732 77.4 76.8–
78.0
8,604 48.5 47.7–
49.2
Democratic Republic of Congo 6,554 6.2 5,909 90.2 89.4–
90.9
6,315 96.4 95.9–
96.8
4,937 75.3 74.3–
76.4
2,799 42.7 41.5–
43.9
Cuba 15,459 14.7 14,773 95.6 95.2–
95.9
15,242 98.6 98.4–
98.8
14,623 94.6 94.2–
95.0
3,431 22.2 21.5–
22.9
Iran 7,179 6.8 6,954 96.9 96.5–
97.3
7,046 98.2 97.8–
98.5
6,787 94.5 94.0–
95.1
5,151 71.8 70.7–
72.8
(Continued)
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Table 3. (Continued)
Characteristics Number and Proportion of Persons Screened
Total Tuberculosis Infection Hepatitis B HIV Hepatitis C
N Col% N Row% χ2
95% CI
N Row% χ2
95% CI
N Row% χ2
95% CI
N Row% χ2
95% CI
Iraq 16,605 15.8 15,062 90.7 90.3–
91.2
16,057 96.7 96.4–
97.0
13,241 79.7 79.1–
80.4
8,229 49.6 48.8–
50.3
Somalia 8,474 8 7,926 93.5 93.0–
94.1
8,085 95.4 95.0–
95.9
6,502 76.7 75.8–
77.6
4,052 47.8 46.8–
48.9
Syria 4,258 4 3,793 89.1 88.1–
90.0
3,985 93.6 92.9–
94.3
2,935 68.9 67.5–
70.3
1,767 41.5 40.0–
43.0
Ukraine 1,485 1.4 1,398 94.1 93.0–
95.3
1,365 91.9 90.5–
93.3
1,153 77.6 75.5–
79.8
1,012 68.2 65.8–
70.5
Other 11,731 11.1 10,910 93.0 92.5–
93.5
11,157 95.1 94.7–
95.5
8,439 71.9 71.1–
72.8
5,724 48.8 47.9–
49.7
Last Residence <0.001 <0.001 <0.001 <0.001
Afghanistan 8,475 8 7,365 86.9 86.3–
87.7
7,905 93.3 92.8–
93.8
6,931 81.8 81.0–
82.6
5,555 65.6 64.6–
66.6
Austria 5,173 4.9 5,035 97.4 97.0–
97.8
5,069 98.1 97.7–
98.4
4,950 95.8 95.2–
96.3
3,813 73.8 72.5–
74.9
Cuba 3,791 3.6 3,603 95.0 94.4–
95.8
3,688 97.3 96.8–
97.8
3,213 84.8 83.6–
85.9
1,494 39.4 37.9–
41.0
Iraq 8,781 8.3 7,761 88.4 87.8–
89.2
8,460 96.4 96.0–
96.8
7,446 84.8 84.1–
85.6
4,176 47.6 46.5–
48.6
Jordan 4,851 4.6 4,322 89.1 88.3–
90.0
4,585 94.5 93.9–
95.2
3,633 74.9 73.7–
76.1
2,244 46.3 44.9–
47.7
Kenya 4,361 4.1 4,043 92.7 92.0–
93.5
4,086 93.7 93.0–
94.4
3,151 72.3 70.9–
73.4
1,954 44.8 43.3–
46.3
Malaysia 11,217 10.6 9,703 86.5 85.9–
87.2
10,651 95 94.6–
95.7
8,991 80.2 79.4–
80.9
5,002 44.6 43.7–
45.5
Nepal 4,319 4.1 3,917 90.7 90.2–
91.9
4,038 93.5 92.8–
94.3
2,843 65.8 64.4–
67.3
2,001 46.3 44.8–
47.8
Thailand 6,363 6 5,941 93.4 93.0–
94.2
5,869 92.2 91.6–
92.9
4,543 71.4 70.3–
72.5
3,561 56 54.7–
57.2
Turkey 5,586 5.3 5,209 93.3 92.7–
94.0
5,416 97 96.5–
97.4
4,653 83.3 82.3–
84.3
3,348 59.9 58.7–
61.2
Other 42,534 40.3 39,632 93.2 92.9–
93.4
41,227 96.9 96.8–
97.1
34,324 80.7 80.3–
81.1
16,632 39.1 38.6–
39.6
Latent Tuberculosis Infection Test
Type
Interferon Gamma Release Assay 85,972 81.5
Tuberculin Skin Test 10,540 10
Not Done 8,939 8.5
Col% refers to proportion of persons with characteristics using the total population (in first column) as denominator, and Row% refers to proportion of persons
screened using stratum-specific (row) total as denominator
aExcludes 10 individuals missing age.
bExcludes 20 individuals missing sex.
c“Other” visa category includes victims of trafficking, unaccompanied minors, and persons with an unspecified visa status.
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus
https://doi.org/10.1371/journal.pmed.1003065.t003
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Table 4. Screening of refugees and other eligible immigrants for parasitic infections by demographic characteristics during domestic medical screening examina-
tions conducted in eighta US sites, 2014–2016.
Characteristics Number and Proportion of Persons Screened
Total Malaria Strongyloides Schistosoma Other
Intestinal Parasites
N Col% N Row% χ2
95% CI
N Row% χ2
95% CI
N Row% χ2
95% CI
N Row% χ2
95% CI
Total 100,677 100.0 16,180 16.1 15.8–
16.3
23,964 23.8 23.5–
24.1
11,155 11.1 10.9–
11.3
56,504 56.1 55.8–
56.4
Age (Years)b <0.001 <0.001 <0.001 <0.001
<5 11,417 11.3 1,489 13.0 12.4–
13.7
3,550 31.1 30.2–
31.9
1,397 12.2 11.6–
12.8
6,658 58.3 57.4–
59.2
5–17 23,492 23.3 3,591 15.3 14.8–
15.7
6,043 25.7 25.2, 26.3 3,137 13.4 12.9–
13.8
12,343 52.5 51.9–
53.2
18–44 51,790 51.4 7,910 15.3 15.0–
15.6
11,444 22.1 21.7–
22.5
5,232 10.1 9.8–10.4 28,808 55.6 55.2–
56.1
45–64 11,298 11.2 2,347 20.8 20.0–
21.5
2,332 20.6 19.9–
21.4
1,182 10.5 9.9–11.0 6,886 61.0 60.1–
61.9
65+ 2,670 2.7 840 31.5 29.7–
33.2
586 22.0 20.4–
23.5
207 7.8 6.7–8.8 1,800 67.4 65.6–
69.2
Examination Year <0.001 <0.001 <0.001 <0.001
2014 32,742 32.5 7,831 23.9 23.5–
24.4
7,299 22.3 21.8–
22.7
3,679 11.2 10.9–
11.6
19,493 59.5 59.0–
60.1
2015 31,924 31.7 7,057 22.1 21.7–
22.6
6,954 21.8 21.3–
22.2
3,697 11.6 11.2–
11.9
17,410 54.5 54.0–
55.1
2016 36,011 35.8 1,292 3.6 3.4–3.8 9,711 27.0 26.5–
27.4
3,779 10.5 10.2–
10.8
19,601 54.4 53.9–
55.0
Sexc <0.001 <0.001 0.1 0.3
Female 47,207 46.9 7,827 16.6 16.3–
16.9
11,576 24.5 24.1–
24.9
5,326 11.3 11.0–
11.6
26,455 56.0 55.6–
56.5
Male 53,450 53.1 8,353 15.6 15.3–
15.9
12,387 23.2 22.8–
23.5
5,828 10.9 10.6–
11.2
30,047 56.2 55.8–
56.6
Visa <0.001 <0.001 <0.001 <0.001
Refugee 69,923 69.5 10,849 15.5 15.2–
15.8
15,622 22.3 22.0–
22.7
8,441 12.1 11.8–
12.3
35,110 50.2 49.8–
50.6
Special Immigrant Visa Holder 11,427 11.4 2,834 24.8 24.0–
25.6
5,236 45.8 44.9–
46.7
249 2.2 1.9–2.5 8,152 71.3 70.5–
72.2
Asylee 3,910 3.9 2,009 51.4 49.8–
53.0
773 19.8 18.5–
21.0
184 4.7 4.0–5.4 3,202 81.9 80.7–
83.1
Cuban/Haitian Entrant
(Parolees)
14,775 14.7 289 2.0 1.7–2.2 2,070 14.0 13.5–
14.6
2,172 14.7 14.1–
15.3
9,584 64.9 64.1–
65.6
Other (Nonrefugees)d 642 0.6 199 31.0 27.4–
34.6
263 41.0 37.2–
44.8
109 17.0 14.1–
19.9
456 71.0 67.5–
74.5
Nationality <0.001 <0.001 <0.001 <0.001
Afghanistan 11,400 11.3 3,027 26.6 25.7–
27.4
5,242 46.0 45.1–
46.9
282 2.5 2.2–2.8 8,434 74.0 73.2–
74.8
Bhutan 3,781 3.8 65 1.7 1.3–2.1 433 11.5 10.4–
12.5
481 12.7 11.7–
13.8
1,344 35.6 34.0–
37.1
Burma 16,402 16.3 593 3.6 3.3–3.9 3,226 19.7 19.1–
20.3
2,477 15.1 14.6–
15.7
6,139 37.4 36.7–
38.2
Democratic Republic of Congo 6,218 6.2 551 8.9 8.1–9.5 1,066 17.1 16.2–
18.1
1,056 17.0 16.1–
17.9
2,005 32.3 31.1–
33.4
Cuba 15,300 15.2 282 1.8 1.6–2.1 2,350 15.4 14.8–
15.9
2,353 15.4 14.8–
16.0
9,892 64.7 63.9–
65.4
(Continued)
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Afghans (46.0%, 95% CI 45.1–46.9), and Somalis (38.3%, 95% CI 37.2–39.3) had the highest
proportion of persons screened for Strongyloides. Screening was highest among persons last
residing in Afghanistan (53.5%, 95% CI 52.4–54.5) or Cuba (50.3%, 95% CI 48.7–51.9). Schis-
tosoma infection screening was reported for 11,155 of 100,677 (11.1%, 95% CI 10.9–11.3)
Table 4. (Continued)
Characteristics Number and Proportion of Persons Screened
Total Malaria Strongyloides Schistosoma Other
Intestinal Parasites
N Col% N Row% χ2
95% CI
N Row% χ2
95% CI
N Row% χ2
95% CI
N Row% χ2
95% CI
Iran 7,141 7.1 3,488 48.8 47.7–
50.0
1,703 23.9 22.9–
24.8
58 0.8 0.6–1.0 6,360 89.1 88.3–
89.8
Iraq 15,970 15.9 3,836 24.0 23.4–
24.7
2,568 16.1 15.5–
16.7
890 5.6 5.2–5.9 8,402 52.6 51.8–
53.4
Somalia 7,928 7.9 887 11.2 10.5–
11.9
3,034 38.3 37.2–
39.3
2,199 27.7 26.8–
28.7
3,481 43.9 42.8–
45.0
Syria 4,171 4.1 216 5.2 4.5–5.9 1,014 24.3 23.0–
25.6
209 5.0 4.4–5.7 2,208 52.9 51.4–
54.5
Ukraine 1,403 1.4 335 23.9 21.7–
26.1
936 66.7 64.3–
69.2
74 5.3 4.1–6.4 1,038 74.0 71.7–
76.3
Other 10,963 10.9 2,900 26.5 25.6–
27.3
2,392 21.8 21.1–
22.6
1,076 9.8 9.3–10.4 7,201 65.7 64.8–
66.6
Last Residence <0.001 <0.001 <0.001 <0.001
Afghanistan 8,170 8.1 2,504 30.6 29.6–
31.6
4,367 53.5 52.4–
54.5
212 2.6 2.3–2.9 6,397 78.3 77.4–
79.2
Austria 5,173 5.1 2,715 52.5 51.1–
53.8
1,127 21.8 20.7–
22.9
36 0.7 0.5–0.9 4,792 92.6 91.9–
93.4
Cuba 3,642 3.6 126 3.5 2.9–4.1 1,831 50.3 48.7–
51.9
1,849 50.8 49.1–
52.4
2,668 73.3 71.8–
74.7
Iraq 8,333 8.3 1,715 20.6 19.7–
21.5
1,335 16.0 15.2–
16.8
461 5.5 5.0–6.0 3,716 44.6 43.5–
45.7
Jordan 4,727 4.7 663 14.0 13.0–
15.0
1,082 22.9 21.7–
24.1
291 6.2 5.5–6.8 2,708 57.3 55.9–
58.7
Kenya 3,989 4.0 411 10.3 9.4–11.3 1,090 27.3 25.9–
28.7
877 22.0 20.7–
23.3
1,506 37.8 36.3–
39.3
Malaysia 10,283 10.2 458 4.5 4.1–4.9 1,528 14.9 14.2–
15.6
332 3.2 2.9–3.6 3,476 33.8 32.9–
34.7
Nepal 3,859 3.8 141 3.7 3.1–4.3 479 12.4 11.4–
13.5
494 12.8 11.8–
13.9
1,290 33.4 31.9–
34.9
Thailand 5,946 5.9 277 4.7 4.1–5.2 1,639 27.6 26.4–
28.7
2,118 35.6 34.4–
36.8
2,282 38.4 37.1–
39.6
Turkey 5,444 5.4 1,645 30.2 29.0–
31.4
1,457 26.8 25.6–
27.9
331 6.1 5.5–6.7 3,817 70.1 68.9–
71.3
Other 41,111 40.8 5,525 13.4 13.1–
13.8
8,029 19.5 19.2–
19.9
4,154 10.1 9.8–10.4 23,852 58.0 57.5–
58.5
Col% refers to proportion of persons with characteristics using the total population (in first column) as denominator, and Row% refers to proportion of persons
screened using stratum-specific (row) total as denominator.
aExcludes data from one site that did not collect information on total numbers of persons screened for these conditions.
bExcludes 10 individuals missing age.
cExcludes 20 individuals missing sex.
d“Other” visa category includes victims of trafficking, unaccompanied minors, and persons with an unspecified visa status.
Abbreviation: CI, confidence interval
https://doi.org/10.1371/journal.pmed.1003065.t004
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Table 5. Screening for sexually transmitted infections of refugees and other eligible immigrants by demographic characteristics during domestic medical screening
examinations conducted in eighta US sites, 2014–2016.
Characteristics Number and Proportion of Persons Screened
Total Syphilis Chlamydia Gonorrhea
N Col% N Row% χ2
95% CI
N Row% χ2
95% CI
N Row% χ2
95% CI
Total 100,677 100 60,713 60.3 60.0–60.6 14,102 14 13.8–14.2 4,687 4.7 4.5–4.8
Age (Years)b <0.001 <0.001 <0.001
<5 11,417 11.3 1,045 9.2 8.6–9.7 75 0.7 0.5–0.8 10 0.1 0.03–0.1
5–17 23,492 23.3 6,705 28.5 28.0–29.1 2,206 9.4 9.0–9.8 753 3.2 3.0–3.4
18–44 51,790 51.4 41,512 80.2 79.8–80.5 10,214 19.7 19.4–20.1 3,226 6.2 6.0–6.4
45–64 11,298 11.2 9,230 81.7 81.0–82.4 1,340 11.9 11.3–12.5 573 5.1 4.7–5.5
65+ 2,670 2.7 2,212 82.9 81.4–84.3 259 9.7 8.6–10.8 125 4.7 3.9–5.5
Exam Year <0.001 <0.001 <0.001
2014 32,742 32.5 19,714 60.2 59.7–60.7 3,047 9.3 9.0–9.6 1,159 3.5 3.3–3.7
2015 31,924 31.7 20,015 62.7 62.2–63.2 4,952 15.5 15.1–15.9 1,490 4.7 4.4–4.9
2016 36,011 35.8 20,984 58.3 57.8–58.8 6,103 17 16.6–17.3 2,038 5.7 5.4–5.9
Sexc <0.001 <0.001 <0.001
Female 47,207 46.9 27,999 59.3 58.9–59.8 8,913 18.9 18.5–19.2 2,459 5.2 5.0–5.4
Male 53,450 53.1 32,712 61.2 60.8–61.6 5,189 9.7 9.5–10.0 2,228 4.2 4.0–4.3
Visa <0.001 <0.001 <0.001
Refugee 69,923 69.5 37,224 53.2 52.9–53.6 10,174 14 14.3–14.8 4,401 6.3 6.1–6.5
Special Immigrant Visa Holder 11,427 11.4 6,634 58.1 57.2–59.0 1,886 16.5 15.8–17.2 25 0.2 0.1–0.3
Asylee 3,910 3.9 3,134 80.2 78.9–81.4 791 20.2 19.0–21.5 10 0.3 0.1–0.4
Cuban/Haitian Entrant (Parolees) 14,775 14.7 13,283 89.9 89.4–90.4 1,111 7.52 7.1–7.9 192 1.3 1.1–1.5
Other (Nonrefugees)d 642 0.6 438 68.2 64.6–71.8 140 21.8 18.6–25.0 59 9.2 7.0–11.4
Nationality <0.001 <0.001 <0.001
Afghanistan 11,400 11.32 6,545 57.4 56.5–58.3 2,172 19.1 18.3–19.8 62 0.5 0.4–0.7
Bhutan 3,781 3.76 1,980 52.4 50.8–54.0 624 16.5 15.3–17.7 293 7.8 6.9–8.6
Burma 16,402 16.3 6,903 42.1 41.3–42.8 2,049 12.5 12.0–13.0 1,371 8.4 7.9–8.8
Democratic Republic of Congo 6,218 6.2 3,032 48.8 47.5–50.0 919 14.8 13.9–15.7 369 5.9 5.4–6.5
Cuba 15,300 15.2 13,642 89.2 88.7–89.7 1,155 7.6 7.1–8.0 231 1.5 1.3–1.7
Iran 7,141 7.1 6,197 86.8 85.7–87.6 1,019 14.3 13.5–15.1 42 0.6 0.4–0.8
Iraq 15,970 15.9 9,883 61.9 61.1–62.6 1,659 10.4 9.9–10.9 373 2.3 2.1–2.6
Somalia 7,928 7.9 3,730 47.1 46.0–48.2 1,686 21.3 20.4–22.2 1,304 16.5 15.6–17.3
Syria 4,171 4.1 1,737 41.6 40.2–43.1 451 10.8 9.9–11.8 102 2.5 2.0–2.9
Ukraine 1,403 1.4 838 59.7 57.2–62.3 453 32.3 29.8–34.7 69 4.9 3.8–6.1
Other 10,963 10.9 6,226 56.8 55.9–57.7 1,915 17.5 16.8–19.2 471 4.3 3.9–4.7
Last Residence <0.001 <0.001 <0.001
Afghanistan 8,170 8.1 4,550 55.7 54.6–56.8 1,648 20.2 19.3–21.0 40 0.5 0.3–0.6
Austria 5,173 5.1 4,635 89.6 88.8–90.4 621 12 11.1–12.9 31 0.6 0.4–0.8
Cuba 3,642 3.6 2,842 78 76.7–79.4 451 12.4 11.3–13.5 197 5.4 4.7–6.1
Iraq 8,333 8.3 5,342 64.1 63.1–65.1 835 10 9.4–10.7 218 2.6 2.3–3.0
Jordan 4,727 4.7 2,350 49.7 48.3–51.1 578 12.2 11.3–13.2 144 3.1 2.6–3.5
Kenya 3,989 4 1,868 46.8 45.3–48.4 801 20.1 18.8–21.3 545 13.7 12.6–14.7
Malaysia 10,283 10.2 4,429 43.1 42.1–44.0 841 8.2 7.7–8.7 436 4.2 3.4–4.6
Nepal 3,859 3.8 1,987 51.5 49.9–53.1 727 18.8 17.6–20.1 318 8.2 7.4–9.1
Thailand 5,946 5.9 2,464 41.4 40.2–42.7 1,241 20.9 19.8–21.9 899 15.1 14.2–16.0
Turkey 5,444 5.4 3,651 67.1 65.8–68.3 910 16.7 15.7–17.7 133 2.4 2.0–2.9
(Continued)
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persons; screening was highest among persons 5–17 years old (13.4%, 95% CI 12.9–13.8).
Parolees (14.7%, 95% CI 14.1–15.3) and refugees (12.1%, 95% CI 11.8–12.3), Somalis (27.7%,
95% CI 26.8–28.7), and persons last residing in Cuba (50.8%, 95% CI 49.1–52.4) had the high-
est proportions of persons screened.
Approximately 56% (95% CI 55.8–56.4) of 100,677 persons were screened for other intesti-
nal parasites, such as Ascaris (Table 4). Screening coverage was highest among asylees (81.9%,
95% CI 80.7–83.1), SIVHs (71.3%, 95% CI 70.5–72.2) and parolees (64.9%, 95% CI 64.1–65.6),
Iranians (89.1%, 95% CI 88.3–89.8), and Afghans (74.0%, 95% CI 73.2, 74.8). Screening was
highest among persons with a last residence in Austria (92.6%, 95% CI 91.9–93.4), Afghanistan
(78.3%, 95% CI 77.4–79.2), and Cuba (73.3%, 95% CI 71.8–74.7).
Among 100,677 persons with screening data for STIs, 60,713 (60.3%, 95% CI 60.0–60.6)
were screened for syphilis (Table 5). Proportions of persons screening differed significantly by
age (χ2 p< 0.001). Screening coverage was lowest among children younger than 5 years (9.2%,
95% CI 8.6–9.7) and 5–17 years (28.5%, 95% CI 28.0–29.1) compared with persons 18 years
and older (80.5%, 95% CI 80.2–80.8, data collapsed from Table 5). Screening was highest
among parolees (89.9%, 95% CI 89.4–90.4) and asylees (80.2%, 95% CI 78.9–81.4).
A smaller proportion of our data set were screened for chlamydia (14,102 of 100,677 per-
sons, 14.0%, 95% CI 13.8–14.2). Chlamydia screening was highest among persons aged 18–44
years, SIVHs and asylees, women, and Ukrainians. Gonorrhea screening results were available
for 4,687 of 100,677 persons (4.7%, 95% CI 4.5–4.8). Screening was highest among persons
18–44 years, refugees, and Somalis.
The majority (31,108 of 35,118; 88.6%, 95% CI 88.3–88.9) of children <17 years of age had
blood lead screening results (Table 6). Screening coverage was significantly lower among chil-
dren�2 years old (82.0%, 95% CI 81.1–82.9) compared with children�3 years old (90.2%,
95% CI 89.9–90.6, data collapsed from Table 6). Screening was highest among refugees (89.8%,
95% CI 89.5–90.2) and lowest among asylees (78.0%, 95% CI 75.6–80.5) and was lower among
children with a last residence in Austria (69.0%, 95% CI 65.2–75.8) compared with other coun-
tries of last residence.
Among the five sites that provided mental health screening data (denominator: 27,712 per-
sons), screening was reported for 10,208 (36.8%, 95% CI 36.3–37.4) persons (Table 6). Mental
health screening was low among children <16 years old (3.9% 95% CI 3.5–4.3, data collapsed
from Table 6); 16 is the age at which mental health screening is recommended in CDC’s Guide-
lines for the U.S. Domestic Medical Examination for Newly Arriving Refugees. Screening among
Table 5. (Continued)
Characteristics Number and Proportion of Persons Screened
Total Syphilis Chlamydia Gonorrhea
N Col% N Row% χ2
95% CI
N Row% χ2
95% CI
N Row% χ2
95% CI
Other 41,111 40.8 26,595 64.7 64.2–65.2 5,449 13.3 12.9–13.6 1,726 4.2 4.0–4.4
Col% refers to proportion of persons with characteristics using the total population (in first column) as denominator, and Row% refers to proportion of persons
screened using stratum-specific (row) total as denominator.
aExcludes data from one site that did not collect information on total numbers of persons screened for these conditions.
bExcludes 10 individuals missing age.
cExcludes 20 individuals missing sex.
d“Other” visa category includes victims of trafficking, unaccompanied minors, and persons with an unspecified visa status.
Abbreviation: CI, confidence interval
https://doi.org/10.1371/journal.pmed.1003065.t005
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Table 6. Screening for blood lead levels and mental health of refugees and other eligible immigrants by demographic characteristics during domestic medical
screening examinations conducted in multiple sites, 2014–2016.
Characteristics Number and Proportion of Persons Screened
Totala Lead Totalb Mental Health
N Col% N Row% χ2
95% CI
N Col% N Row% χ2
95% CI
Total 35,118 100 31,108 88.6 88.3–88.9 27,712 100 10,208 36.8 36.3–37.4
Age (Years)c <0.001 <0.001
�2 6,875 19.6 5,635 82.0 81.1–82.9 1,970 7.1 18 0.9 0.5–1.3
3–6 9,741 27.7 8,867 91.0 90.5–91.6 2,754 9.9 28 1.0 0.6–1.4
7–12 11,836 33.7 10,809 91.3 90.8–91.8 3,457 12.5 37 1.1 0.7–1.4
13–16 6,656 19.0 5,796 87.1 86.3–87.9 2,015 7.3 455 22.6 20.8–24.4
17–44 14,386 51.9 7,861 54.6 53.8–55.5
45–64 2,680 9.7 1,580 59 57.1–60.8
65+ 449 1.6 228 50.8 46.2–55.4
Exam Year <0.001 <0.001
2014 10,761 30.6 9,409 87.4 86.8–88.1 8,940 32.3 2,943 32.9 32.0–33.9
2015 10,722 30.5 9,479 88.4 87.8–89.0 8,226 29.7 3,122 38 36.9–39.0
2016 13,635 38.8 12,220 89.6 89.1–90.1 10,546 38.1 4,143 39.3 38.4–40.2
Sexd 0.03 0.02
Female 17,007 48.4 15,004 88.2 87.7–88.7 13,232 47.7 4,781 36.1 35.3–37.0
Male 18,103 51.5 16,102 89 88.5–89.4 14,466 52.2 5,426 37.5 36.7–38.3
Visa Type <0.001 <0.001
Refugee 27,566 78.5 24,757 89.8 89.5–90.2 23,351 84.3 7,427 31.8 31.2–32.4
Special Immigrant Visa Holder 4,998 14.2 4,270 85.4 84.5–86.4 1,128 4.1 347 30.8 28.1–33.5
Asylee 1,083 3.1 845 78 75.6–80.5 197 0.7 125 63.5 56.7–70.2
Cuban/Haitian Entrant (Parolees) 1,269 3.6 1,067 84.1 82.1–86.1 2,956 10.7 2,257 76.4 74.8–77.9
Other (Nonrefugees)e 202 0.6 169 83.7 78.6–88.8 80 0.3 52 65.0 54.6–75.5
Nationality <0.001 <0.001
Afghanistan 4,986 14.2 4,175 83.7 82.7–84.8 1,249 4.5 360 28.8 26.3–31.3
Bhutan 1,194 3.4 1,098 92 90.4–93.5 2,266 8.2 790 34.9 32.9–36.8
Burma 6,675 19 5,982 89.6 88.9–90.4 7,654 27.6 2,349 30.7 29.7–31.7
Democratic Republic of Congo 3,223 9.2 3,025 93.9 93.0–94.7 3,132 11.3 994 31.7 30.1–33.4
Cuba 1,395 4.0 1,196 85.7 83.9–87.6 3,287 11.9 2,481 75.5 74.0–77.0
Iran 934 2.7 697 74.6 71.8–77.4 100 0.4 51 51.0 41.2–60.8
Iraq 5,515 15.7 4,852 88 87.1–88.8 2,708 9.8 1,089 40.2 38.4–42.1
Somalia 3,795 10.8 3,501 92.3 91.4–93.1 3,026 10.9 844 27.9 26.3–29.5
Syria 2,252 6.4 2,033 90.3 89.1–91.5 1,201 4.3 374 31.1 28.5–33.8
Ukraine 536 1.5 442 82.5 79.2–85.7 297 1.1 75 25.3 20.3–30.2
Other 4,613 13.1 4,107 89 88.1–89.9 2,792 10.1 801 28.7 27.0–30.4
Last Residence <0.001 <0.001
Afghanistan 3,809 10.8 3,163 83 81.9–84.2 891 3.2 265 29.7 26.7–32.7
Austria 577 1.6 398 69 65.2–75.8 9 0 1 11.1 0–48.3�
Cuba 505 1.4 452 89.5 86.8–92.2 2,598 9.4 1,948 75 73.3–76.7
Iraq 3,084 8.8 2,729 88.5 87.4–89.6 1,575 5.7 673 42.7 40.3–45.2
Jordan 2,236 6.4 2,006 98.7 88.5–91.0 1,238 4.5 408 33.0 30.3–35.6
Kenya 1,960 5.6 1,802 91.9 90.7–93.1 1,846 6.7 482 26.1 24.1–28.1
Malaysia 4,027 11.5 3,561 88.4 87.4–89.4 5,337 19.3 1,833 34.4 33.1–35.6
Nepal 1,295 3.7 1,187 91.7 90.2–93.2 2,441 8.8 811 33.2 31.4–35.1
Thailand 2,768 7.9 2,768 93 92.0–93.9 2,362 8.5 482 20.4 18.8–22.0
(Continued)
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persons�16 years old was 54.6% (95% CI 53.9–55.3, data collapsed from Table 6). The pro-
portion of persons who received mental health screening increased slightly between 2014 and
2016, and screening proportion differed by examination year (χ2 p< 0.001). A higher propor-
tion of asylees (63.5%, 95% CI 56.7–70.2) and parolees (76.4%, 95% CI 74.8–77.9) received
mental health screening than refugees (31.8, 95% CI 31.2–32.4) and SIVHs (30.8%, 95% CI
28.1–33.5).
Discussion
This analysis used a multistate data set to describe disease screenings conducted during the
domestic medical examination for refugees and other eligible populations. These results pro-
vide new evidence that most persons eligible for refugee health benefits are screened for several
health conditions after US arrival through the domestic medical examination, particularly for
TB (91.6%), HBV (95.8%), HIV (80.3%), and blood lead (88.6% of persons <17 years old).
Screening coverage for other health conditions, including STIs, parasites, and mental health,
was lower. For most conditions, screening coverage increased with age and differed by nation-
ality and country of last residence. Differences in proportions screened by sex and year of
health assessment, although statistically significant, were not of clinical or public health signifi-
cance for most conditions.
To our knowledge, this is the first analysis of a large, multisite data set to assess screening
coverage resulting from the domestic medical examination recommended for newly arrived
refugees and other eligible visa holders in the US. Our data are consistent with prior studies
that have reported high screening coverage for TB (93%) [16] and HBV (92.5%) during the
domestic medical examination [11,13,16]. Compared with two studies reporting screening
coverage for intestinal parasites among refugees in Minnesota (64%–80%) [16,17], our analysis
found a lower screening coverage among refugees (50.2%). However, the Minnesota studies
predate the current overseas presumptive parasite treatment program for US-bound refugees.
Now, screening for intestinal parasites may be considered based on clinical symptoms and
results of diagnostic testing (e.g., eosinophilia). Reports on screening coverage during the
domestic medical examination for other conditions were lacking for comparison.
Our findings indicate that most persons undergoing the domestic medical examination
receive several routine health screenings recommended in the US, resulting in higher
Table 6. (Continued)
Characteristics Number and Proportion of Persons Screened
Totala Lead Totalb Mental Health
N Col% N Row% χ2
95% CI
N Col% N Row% χ2
95% CI
Turkey 1,764 5.0 1,764 88.2 86.6–89.7 899 3.2 326 36.3 33.1–39.4
Other 13,093 37.3 11,681 89.2 88.7–89.8 8,516 30.7 2,979 35.0 34.0–36.0
Col% refers to proportion of persons with characteristics using the total population (in first column) as denominator, and Row% refers to proportion of persons
screened using stratum-specific (row) total as denominator.
aTotal for lead screening only, excludes persons �17 years old.
bTotal for mental health screening only, excludes persons from four sites not reporting information on mental health screening.
cExcludes 10 individuals missing age.
dExcludes two records with unknown sex for lead, one with unknown sex for mental health.
e“Other” visa category includes victims of trafficking, unaccompanied minors, and persons with an unspecified visa status.
Abbreviation: CI, confidence interval
https://doi.org/10.1371/journal.pmed.1003065.t006
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screening coverage in this population compared with the broader US population for several
conditions. In the US, TB and HBV screening are recommended for populations at highest
risk of infections [18,19], including foreign-born persons from countries with moderate to
high burden of the diseases [20,21]. In our analysis, 91.6% of persons who received a domes-
tic medical examination were screened for TB compared with roughly 63% of all foreign-
born respondents in the 2011–2012 National Health and Nutritional Examination Survey
(self-reported data representative of persons residing in the US) [22]. Almost 96% of per-
sons in our data set were screened for HBV compared with 19% of patients enrolled in four
US healthcare organizations regardless of risk factors (N = 1,248,558) [23]. CDC recom-
mends screening all adults for HIV at least once in their lifetime [24]. We found that 85% of
adults were tested for HIV during the domestic screening examination, which is higher than
the testing rate among the US adult population (<40% in 2016–2017) [24]. Finally, during
the period of this analysis, one-time HCV screening was recommended for all US adults
born between 1945 and 1965, regardless of risk factors [25,26]. The HCV screening rate
among persons in our data set falling into this birth cohort (>44 years old at the time of
their examination) was 56.1% (95% CI 55.3–56.9, data collapsed from Table 3), which is
higher than the HCV screening rate among the general US population born between 1945
through 1965 (13% ever screened in 2015) [27]. The relatively high screening rates for TB,
HBV, HIV, and HCV during the domestic examination demonstrates that the domestic
examination is an effective opportunity to identify eligible new arrivals with these condi-
tions and link them to care in the US. However, efforts to explore why screening opportuni-
ties for these conditions are missed during the domestic medical examination may further
improve screening coverage.
Screening coverage for malaria and intestinal parasites varied widely by visa type, national-
ity, and country of last residence. Screening coverage for malaria and intestinal parasites was
lower among refugees than among other visa holders, which is likely the result of the overseas
presumptive parasite treatment; if complete overseas treatment is documented, domestic
screening is not required [28]. Ukrainians are likely overscreened for Strongyloides infection
based on unclear guidance for screening for refugees originating from Europe, where Strongy-
loides is not hyperendemic [29]. Domestic screening is still recommended for persons who
are symptomatic or have signs of infection such as eosinophilia, those who were ineligible for
overseas treatment because of contraindications, and those from countries where presumptive
treatment is not available.
The CDC Guidelines for the U.S. Domestic Medical Examination for Newly Arriving Refugees
recommend screening for certain STIs based on whether overseas screening was done (for
syphilis), age, and other risk factors, including history of sexual assault [7]. The proportions
of refugees and SIVH screened for syphilis (53% and 58%, respectively) were lower compared
with other visa types, likely reflecting the impact of overseas immigration screening require-
ments for syphilis. Domestic clinicians are recommended to review overseas syphilis testing
results and to repeat testing in the US if overseas results are unavailable. For most of the period
of this analysis, gonorrhea testing was not required overseas (overseas testing began October 1,
2016), and chlamydia testing has never been required overseas. For these infections, the
domestic guidelines recommend screening for patients with certain risk factors (age, sexual
history, or symptoms). Domestic gonorrhea and chlamydia screening among these popula-
tions could reflect presence of risk factors or symptoms, availability of overseas testing results,
clinic screening policies for these conditions, or cultural barriers that discourage refugees from
disclosing risk factors [30].
Blood lead screening was reported for 88.6% of all children <17 years old; children�2
years old had the lowest screening rates (82.0%). CDC’s Guidelines for the U.S. Domestic
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Medical Examination for Newly Arriving Refugees recommend screening children aged 6
months through 16 years for lead upon arrival, but our data did not permit us to uniformly
identify children younger than 1 year. Consequently, 82.0% is likely an underestimate of the
proportion of children appropriately screened in this youngest age group. However, children
aged 1–2 still had lower screening coverage compared with older children. Prior investigations
have found a high prevalence of elevated blood lead levels among refugees [12,31–33], and
infants and young children are at greatest risk of both lead exposures and the resulting negative
health outcomes [33]. Understanding and addressing barriers to lead screening among infants
and young children is critical to ensuring appropriate care. Moreover, results from blood lead
screening performed during the domestic medical exam serve as a baseline for the recom-
mended repeat screening 3–6 months following resettlement that may highlight potential
domestic exposures.
CDC’s Guidelines for the U.S. Domestic Medical Examination for Newly Arriving Refugees
encourage screening for depression and posttraumatic stress disorders (PTSDs) among people
over age 16. In our analysis, mental health screening coverage among adults was between 50%
and 55% and was lowest among refugees (31.8%) and SIVHs (30.8%). The relatively low rate
of mental health screening could be the result of multiple factors. First, immigration-related
screening has historically prioritized infectious disease screening in order to reduce disease
risks to refugees and their resettlement communities. Second, mental health screening may be
deferred from the domestic medical examination, which is typically administered within the
first 90 days of US arrival, because refugees may be in a period of adjustment in which mental
health symptoms are not as apparent [34,35], or they may not feel comfortable disclosing
symptoms during the initial examination [7]. After building a rapport with clinicians, both
care providers and resettled refugees may be better positioned to screen for and address mental
health issues. Finally, research has found that screening is often informally administered,
which may have made it difficult to capture in our data source, and screening may be less likely
to be administered if culturally and linguistically competent mental health services are unavail-
able in the screening jurisdiction for referrals [36,37]. However, we were not able to ascertain
why mental health screening was not done in this analysis. Meta-analyses of mental health
among refugees and other conflict-affected populations have estimated prevalence of depres-
sion (>23%) and PTSDs (also>23%) [38,39] that exceed the estimated prevalence of these
conditions among other populations in the US, such as veterans (PTSD 8%) and the US house-
hold population (depression 7.6%). The high prevalence of mental health conditions coupled
with the low screening coverage in our analysis highlights the need for increased investigation
of when and how mental health screening is being conducted among refugees and other popu-
lations receiving the domestic medical examination, barriers to mental health screening and
services, and effective treatments for these populations.
This analysis was subject to limitations. The data upon which we relied were often collected
primarily for programmatic rather than surveillance purposes, which yielded gaps in informa-
tion (e.g., screening test type). Sites used screening tests and algorithms that may differ in sen-
sitivity and specificity to detect conditions, and they collected and shared data differently.
Therefore, our findings only reflect those sites contributing data and not all refugee and other
persons receiving the domestic medical screening examination in the US. Some sites did not
routinely collect information on each health condition included in the analysis, but this may
not mean that they did not screen for these conditions; conversely, it also is possible that sites
reported testing done outside the domestic medical examination, depending on their source of
data and method of data extraction. One site captured only positive screening outcomes for
parasitic infections and STIs without a denominator of all persons tested; we excluded these
results from our calculations. Screening for some conditions is based on patient age, region of
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origin, or other characteristics (e.g., blood lead, malaria, STIs), so not all patients should have
received screening for each health condition. Screening is done at the discretion of the examin-
ing clinician, with some healthcare providers being more likely to screen for certain conditions
than others; and all screening tests can be declined by the recipients, which may be influenced
by sex, age, cultural factors, and type of testing. We were not able to capture information on
why an individual may not have been screened. Finally, we were unable to collect data on link-
age to care in this population and could not evaluate how well the domestic medical screening
examination connected people to the US healthcare system for further care.
This analysis found that refugees and other recipients of the domestic screening examina-
tion are well screened for several health conditions shortly after arrival in the US. This indi-
cates that the domestic medical examination is effective at its intended purpose to screen
newly resettled persons for health conditions, protecting both their health and the health of
the receiving community. Future directions for research could include exploration of screen-
ing practices during the domestic medical examination, particularly mental health screening,
and assessment of the domestic examination’s effectiveness at connecting recipients to the US
healthcare system.
Our assessment of a large, multisite data set found that screening coverage for several key
health conditions—TB, hepatitis B and C, and HIV—was high during domestic screening
examination, particularly when compared with screening rates among the US population. The
domestic medical examination provides a good opportunity to improve the health of newly
arrived refugees, SIVHs, asylees, and parolees by ensuring they receive several routine recom-
mended health screenings.
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